Neuantigen

Neuantigen is a class of engineered biomolecules designed to elicit specific immune responses through the presentation of antigenic epitopes linked to nanomaterials or nucleic acid scaffolds. The term emerged in the early 2020s as researchers sought to combine the targeting precision of nanotechnology with the versatility of synthetic antigens for vaccine and immunotherapy applications.

The core concept involves conjugating one or more peptide or protein antigens to a carbohydrate, lipid, or polymeric carrier that can enhance delivery to antigen presenting cells. In some formulations, the antigen is embedded within a self‑assembling nanoparticle that mimics the size and surface topology of viral capsids, thereby improving uptake by dendritic cells and subsequent T‑cell activation. Alternatives that incorporate nucleic acid segments encode the target antigen and rely on host cell translation, functioning similarly to mRNA vaccines but with added stability from the carrier matrix.

Neuantigen platforms have been explored for prophylactic vaccines against emerging pathogens such as SARS‑CoV‑2 variants, as well as therapeutic vaccines targeting tumor‑specific neoantigens in solid cancers. Preclinical studies have reported robust humoral and cellular immunity with a favorable safety profile, but clinical data are still limited. Ongoing research focuses on optimizing carrier composition, scaling manufacturing processes, and integrating adjuvant molecules to further enhance immunogenicity.